Sector News

Adynxx merges with Alliqua, snagging Nasdaq listing ahead of pain trials

October 15, 2018
Life sciences

Adynxx is set to gain a Nasdaq listing by merging with Alliqua BioMedical. The reverse merger comes six months after Adynxx committed to advancing pain drug brivoligide, despite the candidate coming up short in a midphase study.

San Francisco-based Adynxx funded the phase 2 trial of brivoligide in postsurgical pain patients with $16 million it raised in a series B round last year. Adynxx has backed away from plans to move the drug straight into phase 3 on the strength of the midphase data. But, with its current development plan centering on two midphase trials featuring a total of 260 patients, it will still need cash.

The merger with Alliqua gives Adynxx a route to investors. Having sold its wound care assets earlier this year, Alliqua has spent the past few months trying to offload anything else of value. Adynxx will take on the Nasdaq listing. A manufacturing facility, Alliqua’s last major asset, is up for sale.

If the deal closes as expected in the first quarter, the resulting company will look a lot like Adynxx. The West Coast biotech’s shareholders will own 86% of the combined company, which will be called Adynxx. Advancing brivoligide will be the top priority of the merged company.

The outstanding question is whether Adynxx can make a success of brivoligide. In phase 2, the EGR1 inhibitor was no better than placebo at reducing pain in the weeks after surgery. That resulted in the trial missing its primary endpoint, but Adynxx looked past the setback and instead focused on data from a subgroup of patients with higher scores on the pain catastrophizing scale (PCS).

Buoyed by the subgroup analysis, Adynxx plans to test brivoligide in patients who have a PCS score of 16 or higher following total knee arthroplasty or mastectomy.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.